Larimar Therapeutics, Inc.
Financials
Valuation Metrics
Larimar Therapeutics, Inc.'s Market Cap is $248M. At end of 2025 it was $325M. Ranked #2926 of 3,116 in US market (top 94%), #1324 of 1,472 on NASDAQ (top 90%), #236 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $248M | US#2,926/3,116 Sec#236/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-173M | US—/3,116 Sec—/265 |
| Total Assets | $165M | US#3,010/3,116 Sec#250/265 |
| Net Assets | $127M | US#2,763/3,116 Sec#208/265 |
| Employees | 71 | US#2,660/3,116 Sec#193/265 |
| Value | ||
| P/B | 1.95x | US#1,365/3,116 Sec#69/265 |
| FCF Yield | -62.86% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -135.50% | US#2,811/3,116 Sec#211/265 |
| Financial Health | ||
| Debt Ratio | 29.77% | US#333/3,116 Sec#103/265 |
| Total Debt | $5M | US#2,894/3,116 Sec#215/265 |
| FCF | $-156M | US#2,726/3,116 Sec#182/265 |
| Cash | $93M | US#2,275/3,116 Sec#181/265 |
| Current Ratio | 4.70x | US#502/3,116 Sec#152/265 |
| Performance | ||
| 1Y Return | -38.56% | US#2,720/3,116 Sec#225/265 |
| 1M Return | -19.26% | US#2,749/3,116 Sec#218/265 |
| From 52W High | -62.77% | US#2,841/3,116 Sec#224/265 |
| 1Y MDD | -66.55% | US#2,871/3,116 Sec#226/265 |
| Trading | ||
| Volume | 598,572 shares | US#1,462/3,116 Sec#146/265 |
| Trading Value | $1M | US#2,820/3,116 Sec#232/265 |
| Per Share | ||
| EPS | $-1.66 | US—/3,116 Sec—/265 |
| BPS | $1.23 | US#2,658/3,116 Sec#194/265 |
Company Info
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.